Can-Fite BioPharma (CANF)
XASE:CANF
Want to see CANF full AI Analyst Report?
Top Page
Can-Fite BioPharma
(NYSE MKT:CANF)
Select Model
Select Model
Rating:41Neutral
Price Target:
$2.50
▼(-38.12% Downside)
Action:Reiterated
Date:03/28/26
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and persistent cash burn) and bearish technical signals (price below key moving averages with negative MACD). Low leverage provides some risk mitigation, but valuation is not supportive given losses and no dividend data.
Positive Factors
Conservative balance sheet / low leverage
Very low leverage meaningfully reduces bankruptcy and refinancing risk for a clinical-stage biotech. A conservative capital structure preserves flexibility to fund trials or negotiate partnerships without immediate debt pressure, improving the company's ability to execute multi-stage development plans.
Negative Factors
Declining revenue and persistent net losses
Material revenue contraction together with widening net losses signal limited commercial traction and ongoing negative economic returns. Persistent unprofitability constrains reinvestment into programs and elevates the likelihood of future equity raises or dilutive financings to sustain development cadence and operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Very low leverage meaningfully reduces bankruptcy and refinancing risk for a clinical-stage biotech. A conservative capital structure preserves flexibility to fund trials or negotiate partnerships without immediate debt pressure, improving the company's ability to execute multi-stage development plans.
Read all positive factors
Can-Fite BioPharma (CANF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.54M
Dividend YieldN/A
Average Volume (3M)258.05K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.90
Shares Outstanding2,142,546
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.07
P/FCF Ratio-0.37
Enterprise Value/Market Cap1.15K
Enterprise Value/Revenue13.49K
Enterprise Value/Gross Profit13.49K
Enterprise Value/Ebitda-848.45
Forecast
1Y Price Target
$6.00Price Target Upside48.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Can-Fite BioPharma Business Overview & Revenue Model
Company Description
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders...
How the Company Makes Money
null...
Can-Fite BioPharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 560.00K | 408.21K | 674.00K | 743.00K | 810.00K | 853.00K |
| Gross Profit | 560.00K | 384.02K | 674.00K | 743.00K | 810.00K | 853.00K |
| EBITDA | -8.90M | -10.00M | -8.12M | -8.18M | -10.08M | -12.83M |
| Net Income | -8.80M | -9.91M | -7.88M | -7.63M | -10.17M | -12.60M |
Balance Sheet | ||||||
| Total Assets | 7.72M | 9.51M | 9.12M | 9.99M | 9.28M | 20.25M |
| Cash, Cash Equivalents and Short-Term Investments | 6.46M | 8.54M | 7.89M | 8.92M | 7.98M | 19.14M |
| Total Debt | 90.00K | 71.00K | 104.00K | 40.00K | 62.00K | 124.00K |
| Total Liabilities | 3.54M | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Stockholders Equity | 4.18M | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
Cash Flow | ||||||
| Free Cash Flow | -8.36M | -9.02M | -7.64M | -8.44M | -10.81M | -9.87M |
| Operating Cash Flow | -8.35M | -9.02M | -7.64M | -8.44M | -10.80M | -9.86M |
| Investing Cash Flow | -2.00K | -2.02K | 1.50M | 498.00K | 9.50M | -14.51M |
| Financing Cash Flow | 10.08M | 9.72M | 6.71M | 9.14M | 0.00 | 20.46M |
Can-Fite BioPharma Technical Analysis
Negative
4.04
Price Trends
3.15
Negative
3.57
Negative
5.92
Negative
Market Momentum
-0.09
Positive
42.79
Neutral
46.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Negative. The current price of 4.04 is above the 20-day moving average (MA) of 3.13, above the 50-day MA of 3.15, and below the 200-day MA of 5.92, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 42.79 is Neutral, neither overbought nor oversold. The STOCH value of 46.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANF.
Can-Fite BioPharma Risk Analysis
Can-Fite BioPharma disclosed 68 risk factors in its most recent earnings report. Can-Fite BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
Can-Fite BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $14.40M | -1.35 | -317.47% | ― | -100.00% | 59.83% | |
44 Neutral | $5.80M | -0.03 | -154.50% | ― | ― | -92.20% | |
42 Neutral | $5.83M | -0.39 | -281.30% | ― | ― | 86.07% | |
41 Neutral | $6.54M | -762.85 | ― | ― | ― | ― |
* Healthcare Sector Average
CANF
Can-Fite BioPharma
2.98
-18.12
-85.88%
GNPX
Genprex
0.59
-12.61
-95.52%
BCDA
BioCardia
0.97
-1.11
-53.51%
PCSA
Processa Pharmaceuticals
2.12
-5.88
-73.50%
PHGE
BiomX
0.52
-9.14
-94.63%
Can-Fite BioPharma Corporate Events
Can-Fite BioPharma Shareholders Approve All Proposals at 2026 Annual Meeting
Jun 4, 2026
On June 4, 2026, Can-Fite BioPharma Ltd. held its Annual General Meeting of Shareholders, where investors voted on five proposals presented by management. The company reported that all five proposals were approved by the required majorities, signa...
Can-Fite BioPharma Posts Positive Phase 2a Signal for Namodenoson in Pancreatic Cancer
Jun 2, 2026
On June 2, 2026, Can-Fite BioPharma reported encouraging clinical observations from its ongoing Phase 2a trial of namodenoson as a monotherapy in pancreatic cancer, where enrollment is complete and several patients have shown prolonged disease con...
Can-Fite BioPharma Adjourns 2026 Shareholder Meeting for Lack of Quorum
May 28, 2026
On May 28, 2026, Can-Fite BioPharma convened its 2026 Annual General Meeting of Shareholders in Ramat Gan, Israel, but the meeting was adjourned for one week due to a lack of quorum. The meeting is now scheduled to be reconvened on June 4, 2026, a...
Can-Fite and Vetbiolix Gain Peer-Reviewed Validation for Piclidenoson in Canine Osteoarthritis
May 18, 2026
On May 18, 2026, Can-Fite BioPharma and Vetbiolix reported that a peer-reviewed article in Frontiers in Veterinary Science described positive study results for Piclidenoson in dogs with osteoarthritis. The oral A3 adenosine receptor agonist signif...
Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data
May 13, 2026
On May 13, 2026, Can-Fite BioPharma announced that, following positive interim results from its ongoing Phase 2a trial in advanced pancreatic adenocarcinoma, it plans to advance its oral A3 adenosine receptor agonist Namodenoson into a Phase 2b st...
Can-Fite Posts Positive Phase 2a Results for Namodenoson in Advanced Pancreatic Cancer
Apr 30, 2026
On April 30, 2026, Can-Fite BioPharma reported positive Phase 2a data for its A3 adenosine receptor agonist namodenoson in advanced pancreatic cancer, showing preliminary clinical activity and durable disease stabilization in a heavily pretreated ...
Can-Fite BioPharma Sets May 28, 2026 AGM to Vote on Share Capital Increase and Executive Option Grants
Apr 23, 2026
On April 23, 2026, Can-Fite BioPharma announced it will hold its 2026 Annual General Meeting of Shareholders on May 28, 2026, at its Ramat Gan headquarters, with shareholders of record as of May 4, 2026, entitled to vote in person or by proxy. The...
Can-Fite and Vetbiolix Complete Phase 2 Enrollment for Canine Osteoarthritis Drug Piclidenoson
Mar 30, 2026
On March 30, 2026, Can-Fite BioPharma announced that its veterinary partner Vetbiolix completed enrollment of 118 client-owned dogs in a randomized, double-blind, placebo-controlled Phase 2 trial of Piclidenoson for osteoarthritis, with treatment ...
Can-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
Mar 26, 2026
On March 26, 2026, Can-Fite BioPharma reported its 2025 results and recent clinical milestones, highlighting that a Phase 2a trial in heavily pretreated pancreatic cancer patients met its primary safety endpoint, with over 30% of patients alive at...
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
Mar 17, 2026
On March 17, 2026, Can-Fite BioPharma announced that the Israeli Patent Office allowed its patent application covering the use of A3 adenosine receptor agonists, including lead candidate Namodenoson, for fat loss and treatment of obesity and relat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.